In this regard, Deng et al. recently demonstrated that the administration of a non-steroidal anti-inflammatory drug to counteract diabetic sarcopenia in a mouse model promoted NOX4 downregulation and reduced ROS production (Deng et al., 2024). Here, NOX4 is linked to diabetes mellitus.